Amendments to the Claims

Please amend the claims as follows:

1-2. (canceled)

3. (currently amended) The formulation according to ~~claim 2~~ claim 24 wherein said liposome comprises a mixture of diacylphosphatidylcholine and diacylphosphatidylglycerol in a molar ratio ranging between 10:1 and 1:1, wherein the acyl chains are either saturated or unsaturated and have between 14 and 18 carbon atoms in length.

4. (previously presented) The formulation according to claim 3, wherein said liposome comprises a polyethyleneglycol derivative of diacylphosphatidylethanolamine.

5. (previously presented) The formulation according to claim 4, wherein the polyethyleneglycol has a molecular weight between about 500 and 5000 daltons.

6. (previously presented) The formulation according to claim 3, wherein the molar ratio is 10:3.

7. (previously presented) The formulation according to claim 4, wherein said liposome comprises a mixture of diacylphosphatidylcholine: diacylphosphatidylglycerol: diacylphosphatidylethanol-amine-polyethyleneglycol in a molar ratio of 10:3:0.1-3.

8. (currently amended) The formulation according to ~~claim 2~~ claim 24, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol in a molar ratio of 10:3 or distearoylphosphatidylcholine:distearoylphosphatidylglycerol in a molar ratio of 10:3.

9. (currently amended) The formulation according to ~~claim 2~~ claim 24, wherein said liposome comprises a mixture of dipalmitoylphosphatidylcholine:dipalmitoylphosphatidylglycerol: dipalmitoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.33 or dipalmitoylphosphatidylcholine: dipalmitoylphosphatidylglycerol: distearoylphosphatidylethanolamine-polyethyleneglycol in a molar ratio of 10:3:0.83.

10. (currently amended) The formulation according to ~~claim 2~~ claim 24, further comprising an additional antibody molecule ~~ligand~~ to one or more proteins selected from a histocompatibility complex protein, a membrane ATPase, thy-1, an interleukin receptor, annexin II, CD3 (T3), CD4 (T4), CD5 (Ti), CD6 (T12), CD8 (T8), CD11a (LFA-1), CD11b (Mac-1), CD11c (gp150,95), CD1 (Lewis X), CD18, CD19, CD25 (Tac), CD30 (Ki-1), CD43 (leukosialin, sialophorin), CD44 (Pgp-1), CD48 (Blast-1), CD54 (ICAM-1), CD55 (DAF), CD59 (protectin, Mac inhibitor), CD63, CD71 (transferrin receptor), CDw108(GR2), cyclophilin A, cytoskeletal proteins and ß 2-microglobulin.

11. (canceled)

12. (currently amended) The formulation according to ~~claim 2~~ claim 24, which further comprises a drug effective against a disease or against the symptoms of a disease caused by said an infectious agent.

13. (currently amended) The formulation according to ~~claim 2~~ claim 24, wherein said HLA-DR protein is present at the membrane surface of a lymphoid cell or a cell of the reticuloendothelial system.

14. (previously presented) The formulation according to claim 12, wherein said HLA-DR protein is present at the membrane surface of a lymphoid cell or a cell of the reticuloendothelial system.

15. (previously presented) The formulation according to claim 13, wherein said HLA-DR protein is acquired by HIV.

16. (previously presented) The formulation according to claim 14, wherein said HLA-DR protein is acquired by HIV.

17. (currently amended) The formulation according to claim 13, ~~wherein said ligand~~ further comprising an additional antibody molecule ~~comprises an additional ligand~~ to one or more of CD4, MHC-I and CD54 proteins.

18. (currently amended) The formulation according to claim 14, further comprising an additional antibody molecule ~~ligand~~ to one or more of CD4, MHC-I and CD54 proteins.

19. (previously presented) The formulation according to claim 12, wherein said drug is selected from AZT, ddI, ddC, 3TC, indinavir, saquinavir, ritonavir, nelfinavir, ganciclovir, foscarnet, ribavirin, amphotericin B and nystatin A.

20. (currently amended) The formulation according to ~~claim 1~~ claim 24, wherein said ~~ligand~~ antibody molecule is an anti-Fab' antibody fragment directed against a HLA-DR protein.

21 – 23. (canceled)

24. (currently amended) A formulation which comprises an antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antibody fragment, said ~~antibody molecule~~ formulation ~~being capable of~~ binding to a HLA-DR protein present at the surface of an infectious agent and at the membrane surface of a cell~~, said ligand being coupled to a lipid-comprising vesicle~~.

25. (new) The formulation of claim 24, wherein said infectious agent is HIV.

26. (new) A formulation which comprises an antibody molecule coupled to a liposome, said antibody molecule being selected from the group consisting of a whole antibody and an antibody fragment, said formulation binding to a HLA-DR protein present at the surface of an infectious agent and at the membrane surface of a cell and delivering a drug to said cell and infectious agent.

27. (new) The formulation of claim 26, wherein said infectious agent is HIV.